Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits with this expensive therapy. Recent data suggest that patients with BCL-6 negative lymphoma are more sensitive to Rituximab therapy. It is also known that patients with high-intermediate and high IPI risk does not benefit form standard three weekly CHOP chemotherapy.
In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit.
We will prospectively treat a group of patients with the following characteristics:
\< 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen: R-CHOP (standard dosis) for 8 cycles
Age
15–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Large B cell Non-Hodgkin Lymphoma CD20+
BCL-6 negative
Age \< 61 years old
ECOG 2 or less
IPI low, low intermediate
Stage II, III or IV
Signed Informed Consent
You may not be if
Stage I
Previous treatment
Lymphomatous central nervous system involvement
Heart disease
Kidney failure (serum creatinine \> 2 mg/dl)
HIV +
Viral Hepatitis
Pregnancy
Clareo Health | Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
